We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $17.50 in the latest trading session, marking a +1.16% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow gained 1.05%, while the tech-heavy Nasdaq added 0.56%.
The infectious disease drug developer's shares have seen a decrease of 3.24% over the last month, not keeping up with the Medical sector's loss of 1.89% and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.57 per share and a revenue of $0 million, signifying shifts of +16.33% and 0%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.66% higher. Adma Biologics currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 20.35. This signifies a discount in comparison to the average Forward P/E of 20.39 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA - Free Report) closed at $17.50 in the latest trading session, marking a +1.16% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow gained 1.05%, while the tech-heavy Nasdaq added 0.56%.
The infectious disease drug developer's shares have seen a decrease of 3.24% over the last month, not keeping up with the Medical sector's loss of 1.89% and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.57 per share and a revenue of $0 million, signifying shifts of +16.33% and 0%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.66% higher. Adma Biologics currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 20.35. This signifies a discount in comparison to the average Forward P/E of 20.39 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.